Clinical Trial: A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis

U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07330934) titled 'A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis' on Dec. 15, 2025.

Brief Summary: This is a multi-center, randomized, double-blind, parallel, placebo-controlled phase 2 clinical study. A total of 403 adult participants with moderate to severe AD are planned to be enrolled to evaluate efficacy, safety, PK characteristics, immunogenicity, and changes in PD characteristics of IBI356.

Study Start Date: Dec. 31, 2025

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis

Intervention: DRUG: Dupilumab

Dupilumab by subcutaneous injection

DRUG: Placebo

Placebo by subcutan...